KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Cash & Current Investments (2016 - 2025)

Moderna (MRNA) has disclosed Cash & Current Investments for 9 consecutive years, with $5.8 billion as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 17.45% to $5.8 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $5.8 billion, a 17.45% decrease, with the full-year FY2025 number at $5.8 billion, down 17.45% from a year prior.
  • Cash & Current Investments was $5.8 billion for Q4 2025 at Moderna, up from $4.5 billion in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $10.7 billion in Q4 2021 to a low of $2.9 billion in Q2 2022.
  • A 5-year average of $6.5 billion and a median of $6.4 billion in 2024 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: surged 535.07% in 2021, then crashed 66.01% in 2022.
  • Moderna's Cash & Current Investments stood at $10.7 billion in 2021, then fell by 7.69% to $9.9 billion in 2022, then dropped by 13.11% to $8.6 billion in 2023, then fell by 18.35% to $7.0 billion in 2024, then fell by 17.45% to $5.8 billion in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Cash & Current Investments are $5.8 billion (Q4 2025), $4.5 billion (Q3 2025), and $5.1 billion (Q2 2025).